Novartis Invest Information

Pharmaceuticals
Novartis's Kisqali Demonstrates a 28.5% Decrease in Recurrence Risk in Early Breast Cancer Patients Sep 17, 2024
Pharmaceuticals
Positive Topline Results for Novartis' Leqvio® in Lowering LDL-C in Low-to-Moderate ASCVD Risk Patients Aug 28, 2024
Pharmaceuticals
Novartis Phase III Trial Shows Atrasentan Promising for IgA Nephropathy Treatment May 26, 2024
Companies
Novartis Scemblix® Outperforms Traditional TKIs in Phase III CML Trial Jan 8, 2024
Stocks
Novartis NVS Receives 'Strong-Buy' Rating from StockNews.com Analysts Nov 28, 2023